Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Expression analysis of human ErbB3 on HEK293/Human ErbB3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB3 Stable Cell Line or negative control cell using PE-labeled anti-human ErbB3 antibody.
Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).
The purity of Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) is more than 85% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Adenocarcinoma of Lung; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Esophageal Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Neoplasms; Glioblastoma; Colonic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
Izalontamab brengitecan | BL-B01D1 | Phase 3 Clinical | SystImmune | Nasopharyngeal Carcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Solid tumours; Digestive System Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Fibroepithelial | Details |
Nezutatug | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Seribantumab | MM-121; SAR-256212; 1N3L70MDFX (UNII code) | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Prostatic Neoplasms; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lung Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Sarcoma; Cholangiocarcinoma; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Kidney Neoplasms; Solid tumours | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
89Zr-Patritumab deruxtecan | Phase 2 Clinical | Daiichi Sankyo Co Ltd, The Netherlands Cancer Institute, Daiichi Sankyo Inc | Carcinoma, Non-Small-Cell Lung | Details | |
IBI-133 | IBI133; IBI-133 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
DB-1310 | DB-1310 | Phase 2 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
SIBP-03 | SIBP-03 | Phase 2 Clinical | Shanghai Institute Of Biological Products Co Ltd | Squamous Cell Carcinoma of Head and Neck; Neoplasms | Details |
SHR-A2009 | SHR-A2009 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) | JK07; SAL-007 | Phase 2 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Heart Failure | Details |
Elgemtumab | NOV-6; LJM-716 | Phase 1 Clinical | Novartis Pharma Ag, Morphosys Ag | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Solid tumours; Neoplasms | Details |
Barecetamab | ISU-104 | Phase 1 Clinical | Isu Abxis Co Ltd | Solid tumours | Details |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
SYS-6023 | SYS-6023; SYS6023 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours | Details |
AMT-562 | AMT-562 | Phase 1 Clinical | Multitude Therapeutics Inc | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
SIBP-A13 | SIBP-A13 | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Head and Neck Neoplasms; Solid tumours; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
Recombinat humanized HER3-targeting antibody | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.